Eli Lilly on Friday said it applied for U.S. approval of its weight loss drug Zepbound for the treatment of the most common sleep-related breathing disorder and expects regulators to make a decision as early as the end of the year.If cleared by the Food and Drug Administration, the company plans to...
Scientific Financial Systems appreciates the power of Snowflake with the scalability, performance, and burstability that it offers our customers. With its recent Snowpark Container Services (SPCS) offering, Snowflake now provides even more value. The allure of SPCS lies not only in its promise of lower latency and enhanced security...
With stocks set to close out a strong first half of 2024, investors have just one more key inflation hurdle to clear in the week ahead: May's personal expenditure report. Stocks have defied all expectations at the midpoint of the year. While many investors came into 2024 anticipating limited...
Jane Fraser, CEO of Citigroup, testifies during the Senate Banking, Housing, and Urban Affairs Committee hearing titled Annual Oversight of the Nations Largest Banks, in Hart Building on Thursday, September 22, 2022. Tom Williams | CQ-Roll Call, Inc. | Getty ImagesBanking regulators on Friday disclosed that they found weaknesses in...
Check out the companies making headlines in midday trading. Sarepta Therapeutics — Shares of the biopharma company surged 33% after the U.S. Food and Drug Administration approved the expanded use of the company's gene therapy Elevidys for Duchenne muscular dystrophy. The FDA granted traditional approval of the therapy for...
